Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share three abstracts supporting the ability of its TissueCypher test to predict risk of progression to esophageal cancer in patients with Barrett’s esophagus (BE) at the Digestive Disease Week (DDW) 2024 Annual Meeting, being held May 18-21, 2024, in Washington, D.C.

“We are committed to advancing care for patients with BE in an effort to reduce the incidence of esophageal cancer and importantly, to help save patients’ lives by informing earlier, potentially life-saving interventions,” said Robert Cook, Ph.D., senior vice president of research and development at Castle Biosciences. “The data we are sharing at DDW 2024 in collaboration with renowned GI experts from the U.S. and abroad further expand the substantial clinical evidence supporting our TissueCypher test and its ability to improve the care that BE patients receive.”

The following abstracts will be presented at DDW 2024 (all times Eastern Time). Abstracts will be available on the DDW ePosters site and to conference attendees in the DDW meeting planner and mobile app after 12:01 a.m. on Sunday, May 19, 2024.

1. Podium presentation title: The Tissue Systems Pathology Test Enables Risk-Aligned Management for Patients with Barrett’s Esophagus
   Presenter and Lead Author: Lucas Duits, M.D., Ph.D., Amsterdam University Medical Centers
   Abstract #: 392
   Session Type: Research Forum
   Session #: 3265
   Session Title: Advances in Barrett's Esophagus
   Date & Time: Sunday, May 19, 11:15-11:30 a.m.
2. Title: The Tissue Systems Pathology Test Predicts Risk of Malignant Progression in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis
   Presenter and Lead Author: Ashley Tran, M.D., Keck School of Medicine, University of Southern California (USC)
   Abstract #: Su1266
   Session Type: Poster Session
   Session #: 7110
   Session Title: Barrett's Esophagus and Esophagogastric Junction Neoplasia - Epidemiology, Risk factors, Screening, Surveillance, Treatment and Outcomes
   Session Date & Time: Sunday, May 19, 12:30-1:30 p.m.
3. Title: The Tissue Systems Pathology Test Provides Clinically Actionable Risk-Stratification in Patients with Barrett’s Esophagus: A Multicenter U.S. Clinical Experience
   Presenter and Lead Author: Harshit Khara, M.D. FACG, FASGE, Geisinger Health System
   Abstract #: Su1267
   Session Type: Poster Session
   Session #: 7110
   Session Title: Barrett's Esophagus and Esophagogastric Junction Neoplasia - Epidemiology, Risk factors, Screening, Surveillance, Treatment and Outcomes